SearcharxivSearch

arXiv subjects

Rashmie Abeysinghe

Publications and source records attributed to Rashmie Abeysinghe.

2 recordsLinked to original sources

Scaling Up Formal Representation of Clinical Trial Protocols in Ensemble Logic Using LLMs: A Preliminary Study

The reliance on unstructured free text for documenting clinical trial protocols creates a significant barrier to automated reasoning, cohort discovery, and trial simulation. The lack of formal structure obscures critical temporal phenotypes, such as dynamic eligibility criteria and event timing constraints. Although Temporal Ensemble Logic (TEL) offers an expressive framework for modeling these elements, manual encoding remains a prohibitive bottleneck. We introduce the CT-TEL workflow: a scalable pipeline leveraging Large Language Models (LLMs) to translate narrative clinical protocols into TEL formulas. We applied CT-TEL to generate logical models for 23 real-world trials from ClinicalTrials.gov. We evaluated translation fidelity via a back-translation approach, using LLMs to convert TEL formulas back into natural language and measuring semantic similarity against source texts. The resulting semantic retention suggests that LLMs may offer a pathway for mapping informal protocols to computable logic, providing preliminary evidence toward scalable clinical trial emulation within the emerging "Symbolic Biomedicine" paradigm championed by the corresponding author.

cs.LO

AD-CDO: A Lightweight Ontology for Representing Eligibility Criteria in Alzheimer's Disease Clinical Trials

Objective This study introduces the Alzheimer's Disease Common Data Element Ontology for Clinical Trials (AD-CDO), a lightweight, semantically enriched ontology designed to represent and standardize key eligibility criteria concepts in Alzheimer's disease (AD) clinical trials. Materials and Methods We extracted high-frequency concepts from more than 1,500 AD clinical trials on ClinicalTrials.gov and organized them into seven semantic categories: Disease, Medication, Diagnostic Test, Procedure, Social Determinants of Health, Rating Criteria, and Fertility. Each concept was annotated with standard biomedical vocabularies, including the UMLS, OMOP Standardized Vocabularies, DrugBank, NDC, and NLM VSAC value sets. To balance coverage and manageability, we applied the Jenks Natural Breaks method to identify an optimal set of representative concepts. Results The optimized AD-CDO achieved over 63% coverage of extracted trial concepts while maintaining interpretability and compactness. The ontology effectively captured the most frequent and clinically meaningful entities used in AD eligibility criteria. We demonstrated AD-CDO's practical utility through two use cases: (a) an ontology-driven trial simulation system for formal modeling and virtual execution of clinical trials, and (b) an entity normalization task mapping raw clinical text to ontology-aligned terms, enabling consistency and integration with EHR data. Discussion AD-CDO bridges the gap between broad biomedical ontologies and task-specific trial modeling needs. It supports multiple downstream applications, including phenotyping algorithm development, cohort identification, and structured data integration. Conclusion By harmonizing essential eligibility entities and aligning them with standardized vocabularies, AD-CDO provides a versatile foundation for ontology-driven AD clinical trial research.

cs.CL